Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Oxaliplatin vs the same regimen including cisplatin Progression‐free survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.88 [0.66, 1.19] | 4 studies · 1034 participants | Low |
Oxaliplatin vs the same regimen including cisplatin Treatment‐related death · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.47 [0.17, 1.3] | 5 studies · 1132 participants | Low |
Combination vs single‐agent chemotherapy Time to progression · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.69 [0.55, 0.87] | 4 studies · 720 participants | Moderate |
Oxaliplatin vs the same regimen including cisplatin Treatment discontinuation due to toxicity · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.97 [0.44, 2.13] | 3 studies · 970 participants | Very low |
Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine) Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.86 [0.71, 1.06] | 3 studies · 482 participants | Very low |
Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine) Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 2.08 [1.37, 3.15] | 3 studies · 482 participants | Low |
Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine) Progression‐free survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.74 [0.59, 0.93] | 3 studies · 482 participants | Moderate |
Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine) Treatment‐related death · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.95 [0.73, 5.17] | 3 studies · 482 participants | Very low |
Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine) Treatment discontinuation due to toxicity · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.71 [0.79, 3.69] | 2 studies · 234 participants | Very low |
S‐1 vs 5‐FU‐containing regimens Overall Survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.91 [0.83, 1] | 4 studies · 1793 participants | High |
S‐1 vs 5‐FU‐containing regimens Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.73 [1.01, 2.94] | 7 studies · 1753 participants | Very low |
S‐1 vs 5‐FU‐containing regimens Progression‐free survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.85 [0.7, 1.04] | 4 studies · 1942 participants | Low |
S‐1 vs 5‐FU‐containing regimens Time‐to treatment failure · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.88 [0.76, 1.01] | 5 studies · 1818 participants | Low |
Combination vs single‐agent chemotherapy Treatment‐related death · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 1.64 [0.83, 3.24] | 18 studies · 3876 participants | Moderate |
S‐1 vs 5‐FU‐containing regimens Treatment‐related deaths · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.56 [0.3, 1.06] | 4 studies · 1962 participants | Moderate |
S‐1 vs 5‐FU‐containing regimens Treatment discontinuation due to toxicity · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 0.85 [0.63, 1.13] | 3 studies · 1726 participants | High |
5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines) Overall survival · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.74 [0.61, 0.89] | 4 studies · 579 participants | Moderate |
5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines) Tumour response · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | OR 2.86 [1.14, 7.16] | 1 study · 78 participants | Low |
5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines) Time to progression · people with advanced gastric cancer Chemotherapy for advanced gastric cancer (2017) · Cochrane | HR 0.62 [0.38, 0.98] | 1 study · 78 participants | Low |
Metronidazole vs vancomycin Symptomatic cure with all exclusions treated as failures · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 0.9 [0.84, 0.97] | 4 studies · 872 participants | Moderate |
Metronidazole vs vancomycin Bacteriologic cure · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 0.85 [0.62, 1.17] | 2 studies · 163 participants | Very low |
Metronidazole vs vancomycin Cure (combined symptomatic and bacteriologic cure) ‐ mild disease · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 0.88 [0.71, 1.09] | 1 study · 90 participants | Very low |
Metronidazole vs vancomycin Cure (combined symptomatic and bacteriologic cure) ‐ severe disease · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 0.74 [0.52, 1.04] | 1 study · 82 participants | Very low |
Teicoplanin vs vancomycin Symptomatic Cure · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 1.21 [1, 1.46] | 2 studies · 110 participants | Very low |
Teicoplanin vs vancomycin Bacteriologic Cure · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 1.82 [1.19, 2.78] | 1 study · 59 participants | Very low |
Fidaxomicin vs vancomycin Symptomatic Cure · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 1.17 [1.07, 1.27] | 2 studies · 1164 participants | Moderate |
Bacitracin vs vancomycin Symptomatic Cure · patients with Clostridium difficile‐associated diarrhoea in adults Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults (2017) · Cochrane | RR 0.58 [0.34, 0.99] | 2 studies · 104 participants | Very low |
Probiotics vs control Incidence CDAD: complete case · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.4 [0.3, 0.52] | 31 studies · 8672 participants | Moderate |
Probiotics vs control Length of Hospital Stay: complete case · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | no estimate extracted | 4 studies · 3484 participants | Moderate |
Probiotics vs control CDAD (baseline risk 0‐2%) · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.77 [0.45, 1.32] | 15 studies · 5845 participants | Moderate |
Probiotics vs control CDAD (baseline risk 3‐5%) · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.53 [0.16, 1.77] | 3 studies · 373 participants | Low |
Probiotics vs control CDAD (baseline risk >5%) · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.3 [0.21, 0.42] | 13 studies · 2454 participants | Moderate |
Probiotics vs control Incidence of C. difficile infection: complete case · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.86 [0.67, 1.1] | 15 studies · 1214 participants | Moderate |
Probiotics vs control Adverse Events: complete case · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.83 [0.71, 0.97] | 32 studies · 8305 participants | Very low |
Probiotics vs control Incidence AAD: complete case · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.58 [0.48, 0.7] | 33 studies · 8870 participants | Low |
Probiotics vs control AAD (Adults) · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.62 [0.51, 0.76] | 23 studies · 7036 participants | Low |
Probiotics vs control AAD (Children) · preventing C. difficile associated diarrhea Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children (2017) · Cochrane | RR 0.38 [0.29, 0.49] | 6 studies · 1141 participants | Moderate |
Bismuth subsalicylate vs placebo Clinical response · patients with active lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 5.25 [0.94, 1.9] | 1 study · 5 participants | Very low |
Bismuth subsalicylate vs placebo Histological response · patients with active lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 1.33 [0.27, 6.6] | 1 study · 5 participants | Very low |
Budesonide vs mesalazine Clinical response · patients with active lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 2.03 [1.25, 3.33] | 2 studies · 57 participants | Low |
Budesonide vs mesalazine Histological response · patients with active lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 2.44 [1.13, 5.28] | 2 studies · 39 participants | Low |
Budesonide vs mesalazine Adverse events · patients with active lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 0.67 [0.12, 3.59] | 1 study · 42 participants | Low |
Mesalazine vs mesalazine + cholestyramine Clinical response · patients with maintenance of remission in lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 0.99 [0.77, 1.28] | 1 study · 41 participants | Low |
Mesalazine vs mesalazine + cholestyramine Histological response · patients with maintenance of remission in lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 0.99 [0.77, 1.28] | 1 study · 41 participants | Low |
Beclometasone dipropionate vs mesalazine Clinical response at 8 weeks · Patients with active or quiescent lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 0.97 [0.75, 1.24] | 1 study · 46 participants | Low |
Beclometasone dipropionate vs mesalazine Maintenance of clinical response at 12 weeks · Patients with active or quiescent lymphocytic colitis Interventions for treating lymphocytic colitis (2017) · Cochrane | RR 1.29 [0.4, 4.18] | 1 study · 46 participants | Very low |
Chemoradiotherapy vs chemoradiotherapy plus surgery Overall survival · nonmetastatic esophageal cancer Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer (2017) · Cochrane | HR 0.99 [0.79, 1.24] | 2 studies · 431 participants | High |
Chemoradiotherapy vs chemoradiotherapy plus surgery Freedom from locoregional relapse · nonmetastatic esophageal cancer Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer (2017) · Cochrane | HR 0.55 [0.39, 0.76] | 2 studies · 431 participants | Moderate |
Chemoradiotherapy vs chemoradiotherapy plus surgery Quality of Life · nonmetastatic esophageal cancer Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer (2017) · Cochrane | no estimate extracted | 1 study · 165 participants | Very low |
Chemoradiotherapy vs chemoradiotherapy plus surgery Treatment‐related mortality · nonmetastatic esophageal cancer Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer (2017) · Cochrane | RR 5.11 [1.74, 15.02] | 2 studies · 431 participants | Low |